|
gptkbp:instanceOf
|
gptkb:drug
gptkb:granulocyte_colony-stimulating_factor
|
|
gptkbp:approvalYear
|
1991
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L03AA02
|
|
gptkbp:biosimilar
|
yes
|
|
gptkbp:brand
|
gptkb:Accofil
gptkb:Grastofil
gptkb:Neupogen
gptkb:Nivestim
gptkb:Zarzio
|
|
gptkbp:CASNumber
|
121181-53-1
|
|
gptkbp:contraindication
|
hypersensitivity to filgrastim
|
|
gptkbp:developedBy
|
gptkb:Amgen
|
|
gptkbp:drugClass
|
colony-stimulating factors
|
|
gptkbp:eliminationHalfLife
|
3.5 hours
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
gptkbp:hasMolecularFormula
|
C845H1343N223O243S9
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
filgrastim
|
|
gptkbp:indication
|
chronic neutropenia
mobilization of hematopoietic progenitor cells
myelosuppressive therapy
reduce infection risk in neutropenic patients
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
stimulates production of neutrophils
|
|
gptkbp:metabolism
|
renal
|
|
gptkbp:origin
|
recombinant DNA technology
|
|
gptkbp:orthologIn
|
endogenous human G-CSF
|
|
gptkbp:pharmacokinetics
|
linear
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:product
|
gptkb:protein
|
|
gptkbp:proteinSequence
|
recombinant human G-CSF
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
intravenous injection
|
|
gptkbp:sideEffect
|
fever
splenomegaly
bone pain
allergic reactions
injection site reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:UNII
|
6U8Z86QG6M
|
|
gptkbp:usedFor
|
bone marrow transplantation
neutropenia
chemotherapy-induced neutropenia
HIV-associated neutropenia
peripheral blood progenitor cell collection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Amgen,_Inc.
gptkb:Neulasta
|
|
gptkbp:bfsLayer
|
7
|